ABBV vs LULU: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Lululemon Athletica Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Lululemon Athletica Inc. · Consumer Cyclical
$116.33
+45.0% upside to fair value
Med Conviction
Grade B-
QuantHub Verdict
LULU has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
LULU |
| Current Price |
$261.07 |
$116.33 |
| Fair Value Estimate |
$264.30 |
$168.68 |
| Upside to Fair Value |
+1.2%
|
+45.0%
|
| Market Cap |
$461.3B |
$13.2B |
| Forward P/E |
128.0x
|
—
|
| EV / EBITDA |
31.0x
|
5.3x
|
| Price / Sales |
7.3x
|
1.2x
|
| Price / FCF |
22.1x
|
10.3x
|
| Revenue Growth YoY |
+12.4%
|
+4.3%
|
| Gross Margin |
70.7%
|
55.7%
|
| Operating Margin |
27.6%
|
18.2%
|
| Return on Equity |
68.0%
|
31.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
9.69%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Lululemon Athletica is a premium athletic-apparel retailer whose technical-product innovation, powerful brand, direct-to-consumer retail and e-commerce model, and community-led marketing have historically supported high returns, including a 31.3% ROE, 55.7% gross margin, 18.2% operating margin, and 13.0% net margin. The investment case is now a turnaround rather than a clean compounding story: in…
Accumulation Zones
| Metric |
ABBV |
LULU |
| Zone Low |
$198.23 |
$126.51 |
| Zone High |
$224.66 |
$143.38 |
| In Buy Zone? |
No
|
Yes
|